postnatal depression

FDA is Expected to Approve Brexanolone for the Treatment of Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  Since that time, Sage Therapeutics [...]

By |2019-03-18T22:49:26-04:00March 18th, 2019|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on FDA is Expected to Approve Brexanolone for the Treatment of Postpartum Depression

Oral Allopregnanolone Analogue for Postpartum Depression Treatment

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of [...]

By |2019-01-13T15:57:09-04:00January 14th, 2019|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Oral Allopregnanolone Analogue for Postpartum Depression Treatment

FDA Supports Intravenous Brexanolone for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  Since that time, Sage Therapeutics [...]

By |2018-11-10T10:02:56-04:00November 10th, 2018|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on FDA Supports Intravenous Brexanolone for Postpartum Depression

In Brief: Asthma Doubles Risk of Postpartum Depression

In a recent study from Quebec, researchers compared the risk of postpartum depression in more than 35,000 pregnant women with asthma and almost 200,000 women without asthma.  They found that rates of postpartum depressive symptoms [...]

By |2018-11-08T10:58:08-04:00October 26th, 2018|Postpartum Depression, Postpartum Psychiatric Disorders, Prevalence & Risk Factors|Comments Off on In Brief: Asthma Doubles Risk of Postpartum Depression

Is Acupuncture Effective for Postpartum Depression?

In a recent meta-analysis, researchers screened electronic databases and analyzed data from randomized controlled trials (RCTs) of acupuncture for the treatment of postpartum depression (PPD). Primary outcomes included improvement in depressive symptoms, as by scores [...]

By |2018-11-08T11:00:14-04:00October 22nd, 2018|Alternative & Complementary, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Is Acupuncture Effective for Postpartum Depression?

Brexanolone for Postpartum Depression: More Data, But Still Some Questions

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors.  We saw the preliminary [...]

By |2018-11-08T11:05:46-04:00September 26th, 2018|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Brexanolone for Postpartum Depression: More Data, But Still Some Questions

After Stillbirth Women Are at Increased Risk for Depression

In the United States, about one out of every 160 pregnancies ends in stillbirth, defined as a pregnancy loss occurring after 20 weeks' gestation.  Perinatal loss is a traumatic event for women and their families. [...]

By |2020-01-13T21:33:54-04:00July 11th, 2018|Depressive Disorders, Infertility and Mental Health, Postpartum Psychiatric Disorders, Pregnancy Loss, Psychiatric Disorders During Pregnancy|Comments Off on After Stillbirth Women Are at Increased Risk for Depression

Brexanolone: A New Drug for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  This drug was initially [...]

By |2018-06-15T11:29:21-04:00June 11th, 2018|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Brexanolone: A New Drug for Postpartum Depression

In Brief: ACOG Recommends Increased Level of Care During the “Fourth Trimester”

The American College of Obstetricians and Gynecologists (ACOG) has made a significant change to its recommendations for optimal postpartum care.  Previously, ACOG has recommended that women receive a single, comprehensive postpartum visit within the first [...]

By |2018-09-10T12:34:21-04:00April 30th, 2018|Postpartum Psychiatric Disorders|Comments Off on In Brief: ACOG Recommends Increased Level of Care During the “Fourth Trimester”

Sacramento: What Can We Learn from a New Mother’s Experience of Postpartum Care?

Over the last few weeks, there has been a lot of coverage of a story involving a new mother from Sacramento.  You can read the details of the story here and here.  Basically, a new [...]

By |2018-03-08T02:33:27-04:00February 9th, 2018|Postpartum Depression, Postpartum Psychiatric Disorders, Treatment|Comments Off on Sacramento: What Can We Learn from a New Mother’s Experience of Postpartum Care?
Go to Top